Skip to main content
RHYTHM PHARMACEUTICALS, INC. logo

RHYTHM PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RYTM ISIN · US76243J1051 LEI · 529900JPNWXQ8DPLA551 US Manufacturing
Open in API
Filings indexed 775 across all filing types
Latest filing 2017-10-03 Regulatory Filings
Country US United States of America
Listing US RYTM

About RHYTHM PHARMACEUTICALS, INC.

https://rhythmtx.com/

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare genetic diseases of obesity. The company's work centers on the melanocortin-4 receptor (MC4R) pathway, a key biological system that regulates hunger and energy expenditure. Its lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved for treating severe obesity and hyperphagia (insatiable hunger) in patients with specific rare conditions, such as Bardet-Biedl syndrome. Rhythm is dedicated to advancing a portfolio of therapies that address the root cause of rare neuroendocrine diseases to improve patient outcomes.

Recent filings

Filing Released Lang Actions
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2017-10-03 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from underwriters to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 and Rule 460 under the Securities Act, and discusses distribution of preliminary prospectuses and compliance with regulations. The document is short (3220 characters) and is a formal communication related to a securities offering registration process, not a financial report or earnings release. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication related to the registration process and not a report or announcement of financial results or corporate actions.
2017-10-02 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 of Regulation C under the Securities Act of 1933 and is signed by the CEO. The content is a formal regulatory communication related to the registration process for securities, not a financial report or earnings release. The document length is short (2137 characters) and it is a request letter, not the actual registration statement or prospectus. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-10-02 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on NASDAQ and references the related Registration Statement on Form S-1. The document is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. Given the nature of Form 8-A as a regulatory filing for securities registration, the appropriate classification is Regulatory Filings (RNS). The document length is 3784 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2017-09-29 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel to the SEC regarding an amendment to a Registration Statement on Form S-1 filed by Rhythm Pharmaceuticals, Inc. The content discusses changes to a proposed reverse stock split and its impact on the company's valuation prior to an IPO. It is a regulatory correspondence related to securities registration and does not contain financial statements or detailed financial results. The document is about a regulatory filing process and amendments to registration documents, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is 5435 characters, which is sufficient for a substantive letter but not a full report. Hence, the classification is RNS with high confidence.
2017-09-27 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a detailed letter from legal counsel to the SEC regarding an Amendment No. 1 to a Registration Statement on Form S-1 filed by Rhythm Pharmaceuticals, Inc. It discusses accounting treatment for stock-based compensation, valuation methodologies for equity, and details related to the IPO price range and stock split. The document references the Management's Discussion & Analysis (MD&A) section of the Amendment No. 1 and provides extensive explanation of valuation methods and fair value determinations. The content is technical and relates to financial disclosures and accounting policies in the context of a registration statement amendment for an IPO. It is not a full annual or quarterly report, nor is it a simple announcement or certification. It is a regulatory filing submitted to the SEC as part of the registration process, supplementing the Form S-1. Given the nature of the document as a supplemental letter responding to SEC comments on a registration statement amendment, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other categories. The document is not a report publication announcement, nor a proxy, nor a capital update, nor a call transcript, etc. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-09-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.